Sesen takes next step after investor attack, calls for shareholder vote to approve merger

Paul Schloesser

Associate Editor

Two and a half weeks after Sesen Bio pushed back against an investor group opposing a merger with Carisma Therapeutics, the biotech is moving forward …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sesen takes next step after investor attack, calls for shareholder vote to approve merger

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sesen takes next step af­ter in­vestor at­tack, calls for share­hold­er vote to ap­prove merg­er

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sesen takes next step after investor attack, calls for shareholder vote to approve merger